Article detail · 2017
A Nationwide Experience With The Off-label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients
Journal
Arthritis Care ResearchISSN 2151-464X
The ISSN points to another catalog journal; the name is from the YÖKSİS record.
- Year
- 2017
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue Arthritis Care Research
- Catalog match (ISSN) Arthritis Care and Research
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
OpenAlex · English
OBJECTIVE: Approximately 30-45% of patients with familial Mediterranean fever (FMF) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine-unresponsive or colchicine-intolerant FMF patients are limited; the most promising alternatives seem to be anti-interleukin-1 (anti-IL-1) agents. Here we report our experience with the off-label use of anti-IL-1 agents in a large group of FMF patients. METHODS: In all, 21 centers from different geographical regions of Turkey were included in the current study. The medical records of all FMF patients who had used anti-IL-1 treatment for at least 6 months were reviewed. RESULTS: In total, 172 FMF patients (83 [48%] female, mean age 36.2 years [range 18-68]) were included in the analysis; mean age at symptom onset was 12.6 years (range 1-48), and the mean colchicine dose was 1.7 mg/day (range 0.5-4.0). Of these patients, 151 were treated with anakinra and 21 with canakinumab. Anti-IL-1 treatment was used because of colchicine-resistant disease in 84% and amyloidosis in 12% of subjects. During the mean 19.6 months of treatment (range 6-98), the yearly attack frequency was significantly reduced (from 16.8 to 2.4; P < 0.001), and 42.1% of colchicine-resistant FMF patients were attack free. Serum levels of C-reactive protein, erythrocyte sedimentation rate, and 24-hour urinary protein excretion (5,458.7 mg/24 hours before and 3,557.3 mg/24 hours after) were significantly reduced. CONCLUSION: Anti-IL-1 treatment is an effective alternative for controlling attacks and decreasing proteinuria in colchicine-resistant FMF patients.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
63 citations
OpenAlex cited_by_count (cache / database)
17 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients 2021
- Successful treatment of coronary artery aneurysm with infliximab in a Behçet's disease patient 2021
- Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever 2020
- The Future of IL-1 Targeting in Kidney Disease 2018
- The Future of IL-1 Targeting in Kidney Disease 2018
- Characteristics and course of patients with AA amyloidosis: single centre experience with 174 patients from Turkey 2023
- Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis 2019
- Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis 2019
- Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same? 2020
- Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same? 2020